Technology Select Sector

S&P 500

The Cannibal

Comparable Companies - LRCX

The insider trading summary shows 1 discretionary purchase and 10 discretionary sales in the last 12 months. The most recent short interest data (2026-02-13) reports a short interest of 2.6% of float. The leading institutional holders are BlackRock, Vanguard Group and State Street Corp.

CHIEF LEGAL OFFICER

DIRECTOR

PRESIDENT AND CEO

CHIEF FINANCIAL OFFICER & EVP

SENIOR VICE PRESIDENT

The filing reports ownership of 129,149,892 shares representing 10.06% of the company's common stock class.

Remains in role as CEO; recently oversaw the transition of the COO and expansion of the board in February 2026.

President and Chief Executive Officer

Remains in role; recently recognized as the 2025 Bay Area CFO of the Year Hall of Fame winner.

Executive Vice President and Chief Financial Officer

Announced retirement on February 3, 2026, effective March 6, 2026, following a 20-year career with Lam and Novellus.

Executive Vice President and Chief Operating Officer

Promoted from SVP, Global Products Group to EVP and COO effective March 6, 2026, to succeed the retiring Patrick Lord.

Executive Vice President and Chief Operating Officer (Incoming)

Joined in July 2024; currently oversees global legal, regulatory, and government affairs.

Senior Vice President and Chief Legal Officer

Role expanded in February 2026 to include oversight of IT, quality, and facilities alongside global manufacturing.

Senior Vice President, Global Operations and Enterprise Solutions

Timothy M. Archer

Douglas R. Bettinger

Seshasayee Varadarajan

Abhijit Y. Talwalkar

Anirudh Devgan

Timothy Archer is a 'provenance' executive whose career is inextricably linked to the consolidation and subsequent dominance of the semiconductor equipment sector. Having transitioned from a key operational role at Novellus to the CEO seat at Lam, he has successfully integrated the two cultures while overseeing a period of unprecedented capital returns. His tenure is defined by 'The Cannibal' strategy—using massive operating cash flows to shrink the share count while maintaining a 50%+ ROIC. His leadership style is characterized by technical rigor and a disciplined approach to the semiconductor cycle, recently pivoting the organization toward 'AI-driven velocity' through a structured leadership succession plan.

Douglas Bettinger is a cornerstone of Lam's financial credibility, possessing a 'Hall of Fame' reputation for disciplined capital allocation. His experience at Intel and Avago provided the blueprint for the high-margin, high-return model he has perfected at Lam. Bettinger is the architect of the company's aggressive buyback program, balancing massive shareholder returns with the R&D investment required to maintain a 54.6% ROIC. His presence on the board of Lattice Semiconductor further validates his status as a leading financial strategist in the semiconductor ecosystem.

Ava Harter brings a high-stakes corporate governance pedigree to Lam, having served as the top legal officer for two major industrial giants (Whirlpool and Owens Corning). Her recruitment in 2024 was a strategic move to bolster Lam's regulatory and government affairs capabilities as the semiconductor industry becomes a focal point of global trade policy. While her tenure at Whirlpool ended due to a structural reorganization, her immediate placement at Lam suggests her expertise in complex global legal strategy is highly valued in the 'AI era' of semiconductor manufacturing.

Michael R. Cannon

Eric K. Brandt

Ita M. Brennan

Sohail U. Ahmed

Bethany J. Mayer

John M. Dineen

Mark Fields

Ho Kyu Kang

Jyoti K. Mehra

Leading supplier of lithography equipment for semiconductor manufacturing.

KLA Corporation provides process control and yield management solutions for the semiconductor industry, enabling customers to improve manufacturing efficiency and product quality.

Teradyne's business model is designed to deliver 40% to 50% incremental operating margin leverage on revenue growth over the long run.

Principal executive, research and development facilities are located in Fremont and Livermore, California; Tualatin, Oregon; Yongin, South Korea; Bengaluru, India; Salzburg and Villach, Austria. Manufacturing and warehouse facilities are located in California, Ohio, Oregon, Austria, Korea, Malaysia and Taiwan. The company owns the Fremont, Livermore, Tualatin, Ohio and Malaysia facilities; the Villach site is leased.

Lam Research, a Mature Compounder with 23.7% FY2025 revenue growth to $18.44B on AI-driven etch/deposition demand, high 48.7% gross margins, and 54.6% ROIC, is stewarded by a strong team under CEO Archer (tenure since 2018) excelling in opportunistic $15.5B buybacks (21.1% yield, 12% share shrink) and track record from Novellus/Lam growth; robust insider ownership and board expertise offset undisclosed incentives and recent net insider sales, though negative incremental ROIC on capex/R&D signals reinvestment risk; overall, exceptional external provenance and returns discipline outweigh alignment gaps, positioning the team well for compounding per-share value.

The company faces risks from increasing and evolving environmental regulations, including those related to hazardous chemicals and PFAS, which could result in fines, remediation costs, operational disruptions, and reputational damage.

As of August 7, 2025, the company had approximately 19,000 regular full-time employees, with 43% located in the United States and over 29% engaged in research and development. In fiscal year 2024, the company terminated approximately 1,760 employees as part of a restructuring plan.

The company provides standard warranties for its products, ensuring they are free from defects in material and workmanship. It indemnifies customers for intellectual property infringement by its products and seeks patents to protect its innovations.

The company relies on a global supply chain and outsource providers, with risks including supplier failures, disruptions, and increased costs. It has efforts to manage these risks, but specific responsible sourcing or community initiatives are not disclosed in the annual filing.

Revenue surged 23.7% to $18.44 bn in FY2025, gross margin rose to 48.7% and operating margin to 32.0%, but incremental ROIC fell to –760.8% as capex and R&D accelerated.

Management described FY2025 capex as focused on manufacturing expansion in Malaysia and Arizona and on new lab capacity, while R&D was directed toward AI‑centric product families (Aqara, Dextro, ALTUS) and advanced packaging tools (SABRE 3D). The FY2026 Q2 transcript reiterated that capex will remain in the 4‑5% of revenue range to support SAM expansion and emerging node entry.

The 2025 10‑K reports no material impairments or plant closures, and the auditor listed inventory valuation as a Critical Audit Matter, suggesting some uncertainty around the $4.04 bn inventory balance. No goodwill or long‑lived asset impairments were disclosed, indicating the asset base is largely intact.

The FY2025 capex surge (to $759 m) and R&D increase were directed at AI‑centric tools, advanced packaging, and manufacturing expansion, yet the negative incremental ROIC suggests these projects have not yet generated cash returns above the 14.5% WACC.

P/FCF

Patrick J. Lord

Ava A. Harter

Seshasayee (Sesha) Varadarajan

BlackRock, Inc.

The Vanguard Group

All current directors and executive officers as a group (17 people)

Christina C. Correia

Ava Harter

Neil J. Fernandes

Timothy Archer

Election of 11 directors to serve until the next annual meeting of stockholders

Election of Directors

Advisory vote to approve the compensation of our named executive officers

Advisory Vote to Approve Named Executive Officer Compensation

Approval of the adoption of the Lam 2025 Stock Incentive Plan

Approval of Lam 2025 Stock Incentive Plan

Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for fiscal year 2026

Ratification of Appointment of Independent Registered Public Accounting Firm

Approval of an amendment to the Company's Restated Certificate of Incorporation to limit the liability of certain officers as permitted by Delaware law

Approval of Amendment to Restated Certificate of Incorporation

Stockholder proposal regarding realistic shareholder ability to call for a special shareholder meeting

Stockholder Proposal

President, Chief Executive Officer & Director

Executive Vice President, Chief Financial Officer

Executive Vice President, Chief Operating Officer

Senior Vice President, Chief Legal Officer and Secretary

Senior Vice President, Global Products Group

Lam Research Corporation, incorporated in 1980 and headquartered in Fremont, California, is a global supplier of innovative wafer fabrication equipment and related services to the semiconductor industry. The company's core competencies include nanoscale manufacturing enablement, chemistry, plasma and fluidics, advanced systems engineering, and a broad portfolio of deposition, etch, and clean products designed to help customers build smaller, higher-performance devices for mobile phones, personal computers, servers, automotive, and data-storage applications.

Manufacturing and servicing of wafer fabrication equipment, including deposition, etch, and clean systems, and providing related customer support services.

Held WACC 14.5% and Base Case terminal multiple 36.0x constant, solved for Year 5 margin to justify current price of 231.

Balance Sheet - Supplemental

Balance Sheet

Cash Flow Statement - Supplemental

Cash Flow Statement

Income Statement - Supplemental

Income Statement

Ratios

Valuation

Historical Ratios & Multiples - LRCX

The semiconductor equipment industry is experiencing strong tailwinds from AI infrastructure, but these are tempered by geopolitical risks and supply chain constraints. While WFE spend is expected to reach $105B in 2025, the industry is entering a peak capital cycle with accelerating capex intensity across the peer group.

Lam Research is at a critical juncture following a major board appointment and the announcement of a COO retirement, all while trading at peak historical multiples and facing intense geopolitical scrutiny.

Normalization of China revenue exposure. Management expects China to represent <30% of 2026 revenue, down from 31% in FY2025. This shift will likely lead to a revenue miss and margin compression as the mix moves toward lower-margin customers.

Realization of negative incremental ROIC. As the market digests that the $759M in recent capex is not yielding returns above the 14.5% WACC, a multiple de-rating is likely.

Geopolitical and Regulatory Risk in China. Further U.S. export controls could permanently impair Lam's ability to serve its largest geographic market, which historically accounts for over 30% of revenue.

Patent Infringement Litigation. Inpria Corporation filed a lawsuit in April 2025 alleging that Lam's Aether Platform unlawfully copied its EUV photoresist technology.

The stewardship verdict is mixed. While the leadership team is highly experienced, the aggressive insider selling ($49.6M net sales) suggests a lack of personal conviction at current price levels. The governance structure is sound, but the leadership transition and geopolitical scrutiny create a high-risk environment for shareholders.

Liquidation value analysis is not relevant for the company's archetype ('Mature_Compounder') and was not performed.

Lam Research appoints Cadence CEO Anirudh Devgan to board of directors

Lam Research price target raised to $180 from $160 at Goldman Sachs

Lam Research price target raised to $200 from $170 at Mizuho

Lam Research replaces Ernst & Young with KPMG as independent auditor

Lam Research reported Q2 2025 financial results with revenue of $4.72 billion and EPS of $1.03.

Market/Sector Move +18.02%

Lam Research reported Q4 2024 financial results with revenue of $4.38 billion and EPS of $0.92.

Lam Research reported Q3 2024 financial results with revenue of $4.17 billion and EPS of $0.86.

Lam Research (LRCX) PT Lowered to $100 at Raymond James

Lam Research announces new CUSIP number following 10-for-1 stock split

Market/Sector Move -6.74%

Lam Research reported Q1 2024 financial results with revenue of $3.87 billion and EPS of $7.78.

Lam Research price target raised to $900 from $865 at Barclays

Lam Research amends bylaws to comply with Delaware law changes

Lam Research reports Q3 2023 financial results showing sequential growth

Lam Research reported Q1 2023 financial results with revenue of $3.87 billion and EPS of $6.01.

Lam Research reported Q4 2022 financial results with revenue of $5.28 billion and EPS of $10.77.

Market/Sector Move +6.85%

Market/Sector Move +12.18%

Lam Research reports Q4 2022 financial results with record revenue

Vanguard Group reports 8.17% ownership stake in Lam Research

FMR LLC and Abigail P. Johnson report 4.991% ownership stake in Lam Research

Lam Research reports Q4 2021 financial results with record calendar year performance

Jefferies Believes Lam Research (NASDAQ: LRCX) Won't Stop Here

Lam Research price target raised to $280 from $175 at Argus

Lam Research price target raised to $265 from $200 at Oppenheimer

Lam Research price target raised to $265 from $220 at Mizuho

Lam Research price target raised to $260 from $195 at Deutsche Bank

Lam Research price target raised to $250 from $160 at Needham

Lam Research upgraded to Overweight from Equal Weight at Wells Fargo

Lam Research price target raised to $250 from $160 at Stifel

Lam Research price target raised to $250 from $200 at Susquehanna

Lam Research price target raised to $265 from $210 at Cantor Fitzgerald

Lam Research price target raised to $200 from $175 at UBS

Lam Research price target raised to $200 from $175 at Jefferies

Lam Research price target raised to $158 from $137 at Morgan Stanley

Lam Research price target raised to $142 from $83 at Barclays

Lam Research initiated with a Hold at HSBC

Lam Research price target raised to $220 from $200 at Mizuho

Lam Research price target raised to $210 from $170 at Cantor Fitzgerald

Lam Research price target raised to $175 from $165 at UBS

Lam Research price target raised to $137 from $125 at Morgan Stanley

Lam Research price target raised to $162 from $130 at Mizuho

Lam Research price target raised to $135 from $115 at Stifel

Lam Research upgraded to Buy from Hold at Deutsche Bank

Lam Research upgraded to Equal Weight from Underweight at Morgan Stanley

Lam Research assumed at Underweight from Equal Weight at Morgan Stanley

Situation: Current price is $233.89 versus fair value $158.37 (-32.3% expected return), and valuation confidence is stable. Debate: Bull case depends on Normalization of China revenue exposure. Bear case centers on Geopolitical and Regulatory Risk in China. Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.

Executive Summary

Lam Research is a high-quality compounding engine currently priced for perfection. While AI infrastructure provides a secular tailwind, the combination of negative incremental returns on recent capital expenditures and aggressive insider selling suggests the stock has overshot its fundamental value.<ul><li>Driver: AI-driven demand for advanced etch and deposition tools.</li><li>Catalyst: Normalization of China revenue and margin compression from customer mix shifts.</li><li>Protection: A fortress balance sheet with $1.9B in net cash and a 100,000-plus chamber installed base.</li></ul>Our variant perception is based on time arbitrage and a more sober assessment of the capital cycle. The market is pricing the stock for a permanent step-change in growth driven by AI, whereas our analysis of the negative incremental ROIC suggests the company is currently in a peak investment phase that will not sustain above-average returns on capital in the near term. We believe the market is underestimating the impact of the planned China revenue decline from 31% to 30%, which will create a significant headwind for both top-line growth and gross margins.This is a valuation-driven exit or avoidance play on a high-quality asset that has reached a cyclical and technical peak. It is predicated on the mean reversion of multiples toward historical averages as the market realizes that recent capex acceleration has not yet yielded returns above the 14.5% cost of capital.

Core Investment Rationale

Lam Research designs and manufactures semiconductor processing equipment used in the fabrication of integrated circuits. The company specializes in deposition and etch processes, which are critical for 3D scaling in NAND and logic. Revenue is split between equipment sales and the Customer Support Business Group (CSBG), which provides spares, upgrades, and services. Strategy is focused on maintaining technology leadership in advanced nodes (Gate-All-Around, HBM) while expanding manufacturing capacity in Malaysia and Arizona to improve operational efficiency. Revenue grew 23.7% YoY to $18.44B in FY2025, driven by AI-driven demand and technology transitions. The company maintains a high-margin profile with operating margins of 32.0% and a TTM ROIC of 61.6%, supported by a rational oligopolistic industry structure.The company's core assets are its proprietary deposition and etch platforms, including the ALTUS, SABRE, and VECTOR systems. These intangible assets form a formidable moat, reinforced by a massive installed base of over 100,000 chambers. This installed base generates high-margin recurring revenue through the CSBG, which reached a record $7.2B in FY2025. Physical assets include owned manufacturing facilities in Malaysia and Oregon, which provide a reliable foundation for capacity expansion.The semiconductor equipment market is a rational oligopoly dominated by Lam Research, Applied Materials, KLA Corporation, and ASML. Lam holds a dominant 45% share in the etch market and 17% in deposition. Competition is based on innovation and yield management rather than price, as evidenced by stable peer margins. However, Lam faces increasing competition from Applied Materials in the transition from Tungsten to Molybdenum in NAND manufacturing.Lam Research has a history of consistent execution and disciplined capital allocation. Under CEO Timothy Archer, who took the helm in 2018, revenue has grown from $11.1B to $18.4B. The company has solidified its leadership through the integration of Novellus Systems and a focus on 3D scaling. Currently, the company is navigating a complex geopolitical environment and a major leadership transition. On February 3, 2026, the company announced the retirement of COO Patrick Lord, effective March 6, 2026, to be succeeded by Sesha Varadarajan. Simultaneously, the company appointed Cadence CEO Anirudh Devgan to its board, a move that was met with an 8.8% share price decline. These changes occur as the company faces a U.S. House Select Committee investigation into its sales practices in China, which historically accounts for over 30% of revenue.

Business & Situation

<ul><li>Bull Case: AI-driven demand for advanced packaging and HBM scaling will sustain double-digit growth; the SABRE 3D platform is becoming a critical bottleneck for AI chip production.</li><li>Bear Case: China revenue normalization will create a significant growth cliff; negative incremental ROIC of -760.8% indicates that recent capex is not yet value-accretive.</li></ul>The consensus view is that Lam Research is a primary beneficiary of the AI revolution, with technology transitions like Gate-All-Around and High-Bandwidth Memory (HBM) driving a permanent expansion of its served addressable market (SAM) to the mid-30s percent of total wafer fabrication equipment (WFE) spend. This narrative has driven the stock to trade at 38.7x EV/EBITDA, a significant premium to its 5-year average of 17.4x.The semiconductor equipment industry is experiencing strong tailwinds from AI infrastructure, but these are tempered by geopolitical risks and supply chain constraints. While WFE spend is expected to reach $105B in 2025, the industry is entering a peak capital cycle with accelerating capex intensity across the peer group.Our differentiated view is that the market is overly focused on short-term AI tailwinds while underappreciating the durability of the moat relative to the current valuation. While the moat is widening, the price paid for that moat is excessive. Management's own actions support this caution: insiders have sold $49.6M in stock over the last 12 months, with the CEO selling 163,300 shares at $163.86. Furthermore, the negative incremental ROIC of -760.8% on $759M of capex suggests that the company is over-investing at the top of the cycle. The recent board appointment and COO transition add layers of execution risk that are not reflected in the current multiple.We conclude that the risk-reward profile is heavily skewed to the downside. The market is paying a peak multiple for peak earnings at a time when internal signals (insider selling) and fundamental metrics (incremental ROIC) are flashing red.Our analytical edge comes from a deeper appreciation of the company's capital cycle and the disconnect between personal insider conviction and corporate capital return actions. By synthesizing the negative incremental ROIC with the aggressive insider divestment, we identify a valuation peak that consensus models overlook.

Core Thesis

CEO Timothy Archer has an exceptional track record, having overseen a 200% stock price increase and a 66% revenue surge during his tenure. However, the upcoming retirement of COO Patrick Lord, a 20-year veteran, creates a significant void in operational leadership at a critical juncture.Management has historically shown strong discipline, returning 85% of free cash flow to shareholders and reducing the share count by 12% over the last five years. However, the recent spike in capex intensity to 4.4% of revenue has yet to produce returns above the cost of capital.Management maintains high credibility with an 80% revenue guidance hit rate, though recent commentary regarding pricing power has been contradicted by guidance for margin compression due to mix shifts.<ul><li>Board Independence: 91% (10 of 11 directors)</li><li>Chairman/CEO Roles: Separate</li><li>Chairman Tenure: 15 years (Abhijit Talwalkar)</li><li>Insider Ownership: 0.3% (3.97M shares)</li><li>Shareholder Rights: No Poison Pill, Written Consent Limited</li></ul>The stewardship verdict is mixed. While the leadership team is highly experienced, the aggressive insider selling ($49.6M net sales) suggests a lack of personal conviction at current price levels. The governance structure is sound, but the leadership transition and geopolitical scrutiny create a high-risk environment for shareholders.

Leadership & Governance

The valuation floor is anchored to the Bear Case DCF value of $158.86, which models a permanent erosion of the company's moat and significant margin compression from a China revenue cliff. Floor value was capped to not exceed the valuation target.The base case assumes 20% revenue growth in Year 1, fading to 10% by Year 5, with operating margins stabilizing at 33%. This results in a fair value of $206.29.The bull case models an AI Packaging Revolution where advanced packaging revenue grows >40%, leading to a blue-sky potential of $250.76.The bear case assumes a China revenue cliff and mix-driven margin compression to 30%, resulting in a valuation floor of $158.86.

Valuation Context

<ul><li>Normalization of China revenue exposure. Management expects China to represent <30% of 2026 revenue, down from 31% in FY2025. This shift will likely lead to a revenue miss and margin compression as the mix moves toward lower-margin customers.</li><li>Realization of negative incremental ROIC. As the market digests that the $759M in recent capex is not yielding returns above the 14.5% WACC, a multiple de-rating is likely.</li><li>Lam Research is at a critical juncture following a major board appointment and the announcement of a COO retirement, all while trading at peak historical multiples and facing intense geopolitical scrutiny.</li></ul>Lam Research is at a critical juncture following a major board appointment and the announcement of a COO retirement, all while trading at peak historical multiples and facing intense geopolitical scrutiny.

Catalyst Path & Context

<ul><li>Geopolitical and Regulatory Risk in China. Further U.S. export controls could permanently impair Lam's ability to serve its largest geographic market, which historically accounts for over 30% of revenue. A February 2025 U.S. House Select Committee investigation into Lam's sales practices in China.</li><li>Patent Infringement Litigation. Inpria Corporation filed a lawsuit in April 2025 alleging that Lam's Aether Platform unlawfully copied its EUV photoresist technology. Ongoing Federal Circuit appeals regarding patent validity.</li><li>The stewardship verdict is mixed. While the leadership team is highly experienced, the aggressive insider selling ($49.6M net sales) suggests a lack of personal conviction at current price levels. The governance structure is sound, but the leadership transition and geopolitical scrutiny create a high-risk environment for shareholders. Risk monitor: Current price $233.89 vs fair value $158.37, expected return -32.3%.</li></ul>

Primary Risks

<ul><li>Entry Target: No new entries: recommendation is Sell.</li><li>Stop Loss: No stop-loss needed because recommendation is Sell (no position).</li><li>Position Size: Position size is None under current recommendation and risk constraints.</li><li>Time Horizon: N/A for a Sell recommendation.</li></ul><ul><li>Management's guidance for the March 2026 quarter already projects gross margin compression to 49% due to mix shifts.</li><li>Incremental 1Y ROIC is currently -760.8%, a sharp reversal from historical levels.</li><li>A February 2025 U.S.</li></ul>A permanent and material acceleration of AI-driven demand that offsets the China revenue cliff and restores incremental ROIC to >20%. Also require valuation reliability to improve before re-entering.

Actionable Parameters & Monitoring

LRCX appears overvalued (fair value $158.37 vs current $233.89, expected return -32.3%). Recommendation: Sell; do not allocate until valuation and risk profile reset.

Final Conclusion

AI-driven demand for advanced etch and deposition tools.

Driver

Normalization of China revenue and margin compression from customer mix shifts.

Catalyst

A fortress balance sheet with $1.9B in net cash and a 100,000-plus chamber installed base.

Protection

AI-driven demand for advanced packaging and HBM scaling will sustain double-digit growth; the SABRE 3D platform is becoming a critical bottleneck for AI chip production.

Bull Case

China revenue normalization will create a significant growth cliff; negative incremental ROIC of -760.8% indicates that recent capex is not yet value-accretive.

Bear Case

Situation: Current price is $233.89 versus fair value $158.37 (-32.3% expected return), and valuation confidence is stable. Debate: Bull case depends on Normalization of China revenue exposure. Bear case centers on Geopolitical and Regulatory Risk in China. Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.

The strategic narrative evolved from a general focus on technology inflections (GAA, HBM, NAND upgrades) driving outperformance to an AI-centric story emphasizing SAM expansion and new product introductions (Dextro, Aqara) as primary growth levers.

Method	Implied Value	Weight	Weighted Value
DCF	$210.14	50%	$105.07
Comps	$118.29	30%	$35.49
Historicals	$89.07	20%	$17.81
Total Weighted			$158.37

LRCX

Company Overview

Price History